https://www.pharma-marketing.com/biomarin-to-acquire-alesta-for-hpp-candidate-ale1/Pharma-Marketing.comen2026-08-20T08:20:27+00:00BioMarin to acquire Alesta for HPP candidate ALE1 https://www.pharma-marketing.com/de/biomarin-uebernimmt-alesta-fuer-hpp-programm-ale1/Pharma-Marketing.comde2026-08-20T08:20:26+00:00BioMarin übernimmt Alesta für HPP-Programm ALE1 https://www.pharma-marketing.com/moderna-reports-positive-phase-3-melanoma-data/Pharma-Marketing.comen2026-08-20T07:38:29+00:00Moderna reports positive Phase 3 melanoma data https://www.pharma-marketing.com/de/moderna-meldet-positive-phase-3-daten-bei-melanom/Pharma-Marketing.comde2026-08-20T07:38:29+00:00Moderna meldet positive Phase-3-Daten bei Melanom https://www.pharma-marketing.com/nim-study-longevity-has-yet-to-become-an-everyday-priority/Pharma-Marketing.comen2026-08-20T07:37:37+00:00NIM study: Longevity has yet to become an everyday priority https://www.pharma-marketing.com/de/nim-studie-longevity-bleibt-im-alltag-noch-ein-nischenthema/Pharma-Marketing.comde2026-08-20T07:37:37+00:00NIM-Studie: Longevity bleibt im Alltag noch ein Nischenthema https://www.pharma-marketing.com/johnson-johnson-publishes-report-on-surgical-intelligence/Pharma-Marketing.comen2026-08-20T07:28:11+00:00Johnson & Johnson publishes report on surgical intelligence https://www.pharma-marketing.com/de/johnson-johnson-legt-report-zu-chirurgischer-intelligenz-vor/Pharma-Marketing.comde2026-08-20T07:28:10+00:00Johnson & Johnson legt Report zu chirurgischer Intelligenz vor